BiykemBozkurt

@hfcollaboratory @yaleHFdoc @coconnormd @ankeetbhatt @mfiuzat @mpsotka @YaleCardiology Congratulations @yaleHFdoc ! So proud of you. Thank you for your leadership and willingness to serve in this important role. Our patients and clinicians will benefit so much from your expertise!

Endlessly proud to celebrate HFC Member Dr. Tariq Ahmad on his appointment as Medical Officer, CDRH, US FDA. Congratulations on this exciting and very well deserved milestone! @yaleHFdoc

Happy to share that the impact factor for #JACCHF increased to 11.9 ! 🏆 Grateful to our exceptional authors, reviewers, readers, Editorial Board, dedicated @JACCJournals staff & #HF community for making this possible. 🙏🏼 @ACCinTouch @ACCmediacenter @BCMHeart @bcmhouston

Baylor College of Medicine honors faculty for excellence in patient care. bit.ly/4u0skmO #BCMFaculty

Baylor College of Medicine celebrates 12 alumni and faculty for excellence in patient care, research and education. bit.ly/45LbdwE #BCMFaculty

Just published in JACC @JACCJournals!🫀 Acute HF care is evolving: 📍Rapid diagnosis 📍Early decongestion 📍Timely GDMT initiation 📍Structured follow-up 📍Focus on long-term outcomes, not just symptom relief Grateful to have contributed to this international collaboration & learned so much from the exceptional experts involved in this work. Congratulations to @Jolie_Bruno_ and @AlexMebazaa for the leadership & to all co-authors on this important publication🫀 Read the full paper🔗: doi.org/10.1016/j.jacc… #HeartFailure #AcuteHeartFailure #JACC @jozinetm @BiykemB @GianluSava @pmyhre

How do we go beyond traditional categorization of patients who don't tolerate GDMT being "stage D"? The reality is that not all these patients need advanced therapies (or at least we think they don't) But we can't address what they need until we know who they are. In comes C2D HF...a framework to define them. An honor to participate in this seminal position statement led by @ShannonMDunlay & the one and only #LynneStevenson in @JACCJournals

We’re honored to rename our DSMB training program the Bristow–DeMets DSMB Academy, recognizing the extraordinary contributions of Michael Bristow, MD, PhD and David DeMets, PhD to clinical trials, patient safety, and the generations of researchers they have inspired. #hfc

Now in @JACCJournals – by #HFC member @BiykemB et al. KDIGO Controversies Conference report addresses the complex, bidirectional relationship between heart failure and chronic kidney disease, highlighting key knowledge gaps and research priorities. jacc.org/doi/10.1016/j.…

Chart your path to leadership 🚀 Join us at ACC.26 for an inside look at leadership journeys in cardiology—real stories, pivotal decisions, and actionable advice to help you grow. 🗓 Mar 28 | ⏰ 1 PM CST 📍 Education Zone Theater 2 ⭐️ Hosted by the ACC FIT Council! #ACC26

Thankful for my coauthors: Jose Lopez, Andrew Sauer, Jonathan Davis, Nasrien Ibrahim, Rod Tung, Biykem Bozkurt, Gregg Fonarow, and Sana Al-Khatib. Link: sciencedirect.com/science/articl…

Recognizing a need to update the 2021 criteria for monitoring disease progression in pts w/ ATTR-CM, a group of international experts shared 🆕 proposed criteria in a recent Position Statement published in #JACCHF. Learn more: bit.ly/48Cybrc #HeartFailure @JACCJournals

Phase I CHILD Trial in #HLHS: Intramyocardial injection of autologous neonatal cardiac progenitor cells during stage II operation was safe/feasible, but didn't improve RV function. Favorable signals for fewer #MACE & 🏥 warrant further research jacc.org/doi/10.1016/j.… #JACCHF

What is the incidence + prevalence of #CKM disease in adults and children who have undergone heart transplant? Read this new piece from the Vanderbilt HTx cohort that explores this key topic now in #JACCHF jacc.org/doi/10.1016/j.…

A series of papers published in #JACCHF provide new findings from the EMPEROR-Preserved trial & several other reports that could benefit the management & treatment of patients w/ #heartfailure, specifically those w/ #HFpEF. Find out more: bit.ly/4tahqM3 @JACCJournals

In ARISE-HF, women with diabetic cardiomyopathy had worse baseline status, yet high-dose AT-001 showed similar efficacy and safety across sexes. jacc.org/doi/10.1016/j.… #JACCHF #DbCM #HeartFailure #T2D #Diabetes @vbluml @JavedButler1 @FaiezZANNAD

In a phase 2 trial, PDE9 inhibition with CRD-740 was well tolerated and increased plasma and urinary cGMP on top of standard care, including sacubitril/valsartan, supporting its potential to enhance natriuretic peptide–cGMP signaling in HF. jacc.org/doi/10.1016/j.… #JACCHF

LVADs are increasingly implanted in AHF patients as destination therapy. @PalakShahMD @ShashankSinhaMD discuss issues related to GDMT in these patients in an editorial on a study in #JACCHF of effects of HF medical therapy from ARIES-HM3 @coconnormd jacc.org/doi/10.1016/j.… jacc.org/doi/10.1016/j.…

New @JACCJournals #JACCHF position statement: everything you want to know re: ischemic heart disease in pts w #HF 🔹Which meds & when 🔹Role of ischemia & viability testing 🔹Patient selection & timing for revasc 🔹Areas for further research jacc.org/doi/10.1016/j.…

High CS mortality highlights limits of focusing only on cardiac output. In ACHF-CS, systemic dysfunction evolves alongside hemodynamic collapse. Future therapies must go beyond macrocirculatory rescue to 🎯 peripheral drivers of shock & recovery jacc.org/doi/10.1016/j.… #JACCHF